Prognostic value of interleukins 6 and 8 in assessing the effectiveness of therapy in patients with triple-negative breast cancer
https://doi.org/10.17650/1726-9784-2025-24-4-39-46
Abstract
Background. Interleukin (IL) 6 is a potent proinflammatory pleiotropic cytokine and is a key factor in the immune escape of malignant cells. IL-8 (or CXCL8) is a proinflammatory chemokine, high levels of expression of which were observed in various types of cancer.
Aim. To determine the relationship between the level of IL-6 and IL-8 cytokines in the blood serum with the main populations of peripheral blood lymphocytes and its significance for the results of neoadjuvant chemotherapy for triple-negative breast cancer (TN BC).
Materials and methods. All 64 patients received chemotherapy and surgery. The concentrations of IL-6 and IL-8 (ng / ml) in the blood serum and the percentage of the main lymphocyte populations in the peripheral blood (PB) were determined.
Results. The relationship between progression, metastasis and death of patients with higher IL-6 concentrations in the blood serum of patients with TN BC was demonstrated. Before treatment, a positive correlation was found between the IL-6 level and the percentage of HLA-DR, CD3+HLA-DR+, CD3–HLA-DR+ lymphocytes, which, as previously shown, are negative prognostic factors in TN BC. An increase in the IL-6 level was combined with a decrease in the percentage of CD4+ T lymphocytes.
Conclusion. The obtained results are consistent with the position that IL-6 is a negative prognostic factor in patients with BC. The positive relationship between IL-6 and “negative” HLA-DR, CD3+HLA-DR+, CD3‒HLA-DR+ lymphocyte populations found in the work indicates their interaction in stimulating tumor growth.
Supporting agencies: The work was carried out within the framework of the research topic No. И123021000086-7.
About the Authors
A. I. Chertkova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Antonina I. Chertkova
24 Kashirskoe Shosse, Moscow 115522
I. B. Shoua
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Ilona B. Shoua
24 Kashirskoe Shosse, Moscow 115522
A. A. Borunova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Anna A. Borunova
24 Kashirskoe Shosse, Moscow 115522
Z. G. Kadagidze
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Zaira G. Kadagidze
24 Kashirskoe Shosse, Moscow 115522
S. L. Gutorov
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Sergey L. Gutorov
24 Kashirskoe Shosse, Moscow 115522
T. N. Zabotina
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Tatiana N. Zabotina
24 Kashirskoe Shosse, Moscow 115522
References
1. Kadagidze Z.G. Cytokines. Prakticheskaya onkologiya = Practical Oncology 2003;4(3):131–9. (In Russ.).
2. Habanjar O., Bingula R., Decombat C. et al. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci 2023;24(4):4002. DOI: 10.3390/ijms24044002
3. Kureshi C.T., Dougan S.K. Cytokines in cancer. Cancer Cell 2025;43(1):15–35. DOI: 10.1016/j.ccell.2024.11.011
4. Briukhovetska D., Dörr J., Endres S. et al. Interleukins in cancer: from biology to therapy. Nat Rev Cancer 2021;21(8):481–99. DOI: 10.1038/s41568-021-00363-z
5. Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol 2021;33(3):127–48. DOI: 10.1093/intimm/dxaa078
6. Masjedi A., Hashemi V., Hojjat-Farsangi M. et al. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. Biomed Pharmacother 2018;108:1415–24. DOI: 10.1016/j.biopha.2018.09.177
7. Knüpfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 2007;102(2):129–35. DOI: 10.1007/s10549-006-9328-3
8. Raza S., Rajak S., Tewari A. et al. Multifaceted role of chemokines in solid tumors: From biology to therapy. Cancer Biol 2022;86(Pt 3):1105–21. DOI: 10.1016/j.semcancer.2021.12.011
9. Dethlefsen C., Hojfeldt G., Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat 2013;138(3):657–64. DOI: 10.1007/s10549-013-2488-z
10. Hailemichael Y., Johnson D.H., Abdel-Wahab N. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 2022;40(5):509–23.e6. DOI: 10.1016/j.ccell.2022.04.004
11. Sansone P., Storci G., Tavolari S. et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117(12): 3988–4002. DOI: 10.1172/JCI32533
12. Kadagidze Z.G., Chertkova A.I., Zabotina T.N. et al. The relationship of markers of early and late lymphocytes activation with the effectiveness of neoadjuvant chemotherapy in patients with triple negative breast cancer with the efficiency of neoadjuvant chemotherapy in triple negative breast cancer patients. Immunologiya = Immunology 2021;42(2):112–24. (In Russ.). DOI: 10.33029/0206-4952-2021-42-2-112-124
13. Borst J., Ahrends T., Bąbała N. et al. CD4+ T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 2018;18(10):635–47. DOI: 10.1038/s41577-018-0044-0
14. Huang R., Wang Z., Hong J. et al. Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy. Cell Death Dis 2023;14(10):703. DOI: 10.1038/s41419-023-06230-z
Review
For citations:
Chertkova A.I., Shoua I.B., Borunova A.A., Kadagidze Z.G., Gutorov S.L., Zabotina T.N. Prognostic value of interleukins 6 and 8 in assessing the effectiveness of therapy in patients with triple-negative breast cancer. Russian Journal of Biotherapy. 2025;24(4):39-46. (In Russ.) https://doi.org/10.17650/1726-9784-2025-24-4-39-46
Views:
89
Email this article 